Abstract

Anal squamous cell carcinoma (SCC) will be diagnosed in an estimated 9,080 adults in the United States this year, and rates have been rising over the last several decades. Most people that develop anal SCC have associated human papillomavirus (HPV) infection (~85–95%), with approximately 5–15% of anal SCC cases occurring in HPV-negative patients from unknown etiology. This study identified and characterized the Kras-driven, female sex hormone-dependent development of anal squamous cell carcinoma (SCC) in the LSL-KrasG12D; Pdx1-Cre (KC) mouse model that is not dependent on papillomavirus infection. One hundred percent of female KC mice develop anal SCC, while no male KC mice develop tumors. Both male and female KC anal tissue express Pdx1 and Cre-recombinase mRNA, and the activated mutant KrasG12D gene. Although the driver gene mutation KrasG12D is present in anus of both sexes, only female KC mice develop Kras-mutant induced anal SCC. To understand the sex-dependent differences, KC male mice were castrated and KC female mice were ovariectomized. Castrated KC males displayed an unchanged phenotype with no anal tumor formation. In contrast, ovariectomized KC females demonstrated a marked reduction in anal SCC development, with only 15% developing anal SCC. Finally, exogenous administration of estrogen rescued the tumor development in ovariectomized KC female mice and induced tumor development in castrated KC males. These results confirm that the anal SCC is estrogen mediated. The delineation of the role of female sex hormones in mediating mutant Kras to drive anal SCC pathogenesis highlights a subtype of anal SCC that is independent of papillomavirus infection. These findings may have clinical applicability for the papillomavirus-negative subset of anal SCC patients that typically respond poorly to standard of care chemoradiation.

Highlights

  • IntroductionThis study presents a novel etiology for human papillomavirus (HPV)-negative anal squamous cell carcinoma (SCC) development driven by mutant Kras

  • We identified that LSL-KrasG12D; pancreatic and duodenal homeobox 1 (Pdx1)-Cre (KC) mice showed female-specific anal squamous cell carcinoma (SCC) development

  • These studies focused on concomitant genetic mutations (e.g., Trp53, Ink4a/Arf) [9, 34] or the influence of environmental changes [35] in addition to the Pdx1-Cre driven KrasG12D-mutation, which facilitate the onset of pancreatic ductal adenocarcinoma (PDAC) and consequent death at an early age

Read more

Summary

Introduction

This study presents a novel etiology for HPV-negative anal SCC development driven by mutant Kras. Mutant Kras is identified in 10% of HPV-negative anal SCC samples [7] Despite this association, to our knowledge, the present study is the first to identify this correlation in a pre-clinical model. The mutant Kras-driven development of anal SCC was detected in a genetically engineered mouse model (GEMM) traditionally used in the investigation of pancreatic ductal adenocarcinoma (PDAC). This mouse harbors a Kras-mutation (Kras G12D) in cells expressing Cre-recombinase from pancreatic and duodenal homeobox 1 (Pdx1) promoter (KC mice: Lox-stop-lox KrasG12D/+; Pdx1-Cre) [8]. We observed that only female mice developed anal SCC suggesting a sex-hormone dependent interaction with Kras G12D that triggers tumor formation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call